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Abstract
Modifiable risk factors, such as diet, are becomingly increasingly important in the management of
cardiovascular disease, one of the greatest major causes of death and disease burden. Few studies
have examined the role of diet as a possible means of reducing arterial stiffness, as measured by
pulse wave velocity, an independent predictor of cardiovascular events and all-cause mortality.
The aim of this study was to investigate whether dairy food intake is associated with measures of
arterial stiffness including carotid-femoral pulse wave velocity and pulse pressure. A cross-
sectional analysis of a subset of the Maine Syracuse Longitudinal Study sample was performed. A
linear decrease in pulse wave velocity was observed across increasing intakes of dairy food
consumption (ranging from never/rarely to daily dairy food intake). The negative linear
relationship between pulse wave velocity and intake of dairy food was independent of
demographic variables, other cardiovascular disease risk factors and nutrition variables. The
pattern of results was very similar for pulse pressure, while no association between dairy food
intake and lipid levels was found. Further intervention studies are needed to ascertain whether
dairy food intake may be an appropriate dietary intervention for the attenuation of age-related
arterial stiffening and reduction of cardiovascular disease risk.
Keywords
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Introduction
Cardiovascular disease (CVD) is one of the leading causes of death and disease burden in
Europe, the United States, and Australia. As populations age, the risk, prevalence and cost of
CVD is likely to increase further. Positive modifiable risk factors for CVD, including diet,
will become increasingly important to alter the course of this disease.
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Dairy foods and milk products have received a negative reaction in the media in the recent
past, largely due to the association between saturated fatty acids (SFA) and CVD risk, and
the high SFA content in dairy foods. However, a number of recent reviews of milk and dairy
consumption and CVD have concluded that dairy foods are not associated with a higher risk
of CVD, and indeed may offer some benefit. The Dietary Approaches to Stop Hypertension
study (DASH), was one of the first studies to show that a diet high in low-fat dairy can have
beneficial effects on blood pressure (BP)1. Following the DASH diet, high in fruit,
vegetables, and low-fat dairy products (approximately three serves per day), for six months
was associated with greater reduction in systolic BP (SBP) and diastolic BP (DBP) than
either a control diet or a weight-reducing diet, among men and women. These reductions
were in the range of 11 to 12 mmHg for SBP and 6 to 7 mmHg for DBP1. Although the
individual contributions of low-fat dairy on BP could not be determined from this
combination diet, the DASH researchers attributed the beneficial BP effect to the high intake
of dairy-rich calcium and potassium in the DASH diet. Evidence with respect to
consumption of milk and dairy products in relation to BP reduction has been summarized in
a recent review of the literature2. Based on results from 11 cross-sectional and eight
prospective studies, it was concluded that increased dairy food consumption is associated
with lower SBP and lower risk for hypertension, particularly for low-fat dairy food. A recent
intervention study has also demonstrated a reduction in SBP following an intake of three
serves of low-fat dairy products per day for two months3.
Traditionally, BP is measured by assessing the pressure in the brachial artery in the upper
arm and arterial stiffness is assessed by way of pulse pressure (PP; SBP - DBP). However it
is becoming increasingly recognised that measures of central arterial function, i.e. measures
of arterial stiffness, are more valuable predictors of vascular health outcomes4. The central
arteries slowly stiffen with age, with the rate influenced by hypertension, diabetes and
atherosclerosis5. Pulse wave velocity (PWV) is now considered the gold standard non-
invasive method for measuring arterial stiffness, and is an independent predictor of
cardiovascular events and all-cause mortality6,7.
There have been few studies on the role of micronutrients in the treatment of arterial
stiffness. A recent review showed support for the intake of omega-3 fish oils, and soy
isoflavones, as well as consumption of fermented milk products containing bioactive
peptides8. Studies evaluating the relationship between milk and dairy products and holistic
markers of CVD risk, such as arterial stiffness have been recommended9, as has research to
examine the role of micronutrients in the treatment of arterial stiffness8. The aim of our
study was to examine dairy food intake per se, in relation to measures of arterial stiffness via
carotid-femoral PWV (cfPWV), PP, and other indices of cardiovascular health including
SBP and DBP.
Methods
Participants
Participants were obtained from the Maine-Syracuse Longitudinal Study (MSLS), a study
designed to examine cardiovascular risk factors in relation to cognitive performance in
community-dwelling individuals. The MSLS consists of five cohorts defined by time of
entry into the study (1975–2000). Recruitment and data collection procedures for the MSLS
have been previously described in detail10. The data for the present study were obtained
from those participants returning for the seventh study wave, as both cfPWV and dietary
intake measures were both obtained at this examination for the first time.
From an initial sample of 626 individuals with cfPWV data at wave 7, participants were
excluded in the following order: history of stroke (n = 14), probable dementia (n = 2),
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inability to read English (n = 1), missing data on dairy consumption (n = 3), or suboptimal
quality of data on arterial stiffness as defined a priori as a cfPWV error of estimate >20% (n
= 19). Dementia and stroke were reasons for exclusion because we were interested in
examining relationships between diet and arterial stiffness in a community-dwelling,
relatively healthy study population. The characteristics of the final sample with complete
data (N = 587) are presented in Table 1.
The University of Maine Institutional Review Board approved this study, and the use of de-
identified MSLS data was approved by the University of South Australia Human Ethics
Committee. All participants provided informed consent for data collection, and all
procedures followed were in accordance with institutional guidelines.
Procedure
Within two weeks of the laboratory visit, participants completed the Center for
Epidemiologic Studies Depression Scale (CES-D)11, the Nurses’ Health Study Activity
Questionnaire12, and the Nutrition and Health Questionnaire13. At this visit, a blood sample,
brachial artery BP, and pulse wave measures were obtained prior to breakfast, following an
overnight fast. Standard assay methods were employed10,14 to obtain total cholesterol, high
density lipoprotein (HDL) and low density lipoprotein (LDL) cholesterol, triglycerides,
fasting plasma glucose, and plasma homocysteine. After a light breakfast, including
decaffeinated tea or coffee, participants underwent a medical interview including a detailed
medical history.
BP and cfPWV assessment
Brachial artery pressures were measured in accordance with the procedure at prior MSLS
waves, taken five times each in reclining, sitting and standing after a supine rest for 10
minutes, with a five minute rest between each set of measures. Measures were taken using
the traditional pressure-cuff method (Critikon Dinamap ProCare 100, oscillometric method).
In a supine position, cfPWV was assessed non-invasively using the SphygmoCor system
(AtCor Medical) with applanation tonometry. The carotid-femoral path length was estimated
as the surface distances joining the suprasternal notch, the umbilicus, and the femoral pulse
subtracted from distance between the suprasternal notch and the carotid pulse. Carotid-
femoral transit time was estimated in 8 to 10 sequential ECG-gated femoral and carotid
waveforms as the average time difference between the onset of the femoral and carotid
waveforms. The intersecting tangent method was employed to identify the foot of the pulse
wave. PWV was calculated as the carotid-femoral path length divided by the carotid-femoral
transit time, a reproducible measure of central arterial stiffness6.
Dietary assessment
Diet was assessed using The Nutrition and Health Questionnaire, which comprises 41
questions about dietary intake, smoking history, physical activity, marital status, medical
history, self-reported health, and medication and supplement use13,15. The questionnaire has
been used in a large investigation of cancer and nutrition and its acceptable validity has been
demonstrated by comparison with dietary recall, protein excretion and total energy
expenditure data16. The dietary component questions participants about their frequency of
consumption of meat, fish, dairy products, eggs, breads, cereals, and beverages including
tea, coffee, carbonated drinks, water, fruit juice, and alcohol. A comprehensive list of 37
foods follows, and participants are required to stipulate how frequently they consume each
food, with six response options: never; seldom; once a week; 2 to 4 times a week; 5 to 6
times a week; or once or more a day. These six response options were used to form the five
level categorization of total dairy food consumption, with the never and seldom respondents
grouped together due to the low numbers in each category. Dairy products included were
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milk, cheese, yoghurt and dairy desserts (grouped together), ice-cream and cream (grouped
together), and total dairy foods. Milk was the only dairy food for which participants were
asked to stipulate the fat content of milk consumed (whole fat, reduced fat, or skim). Milk
intake included milk on cereal and in other beverages such as tea and coffee. Soy milk
intake was not included in any analyses of dairy and cfPWV.
The median score within each response option was used to estimate total intakes per week
for each food in the questionnaire; for example, 2 to 3 times per week was estimated at 2.5.
These totals were used to determine mean daily intakes for each food. As portion sizes were
not stipulated, the totals are an estimate of the number of times each food was consumed on
a daily basis. Individual foods were grouped into five major food categories (in addition to
dairy products) - grains, fruits, vegetables, protein foods, and fats/sweets/other (empty
calories) - based on the USDA MyPlate17. Intakes of individual foods and beverages within
each food group were summed to give an estimate of total intake for each group, and intakes
for all food groups were added to estimate total energy intake. The primary predictor
variable in this study was the five level categorization of total dairy food consumption.
Covariates
Variables that were measured at the physical examination and were considered as candidates
for inclusion in the covariate sets included height, weight, body mass index (BMI), waist
circumference, and prevalent obesity, diabetes, hypertension, and CVD. BMI was calculated
from height and weight (kg/m2), and obesity was defined as BMI of 30 kg/m2 or above.
Waist circumference was measured over light clothing, using a non-extendable tape at the
level of the iliac crest. Diabetes mellitus was defined as treatment with insulin, oral
antidiabetic agents, or by fasting glucose level of 7 mmol/L or above. Hypertension was
defined as treatment for hypertension or a BP of ≥ 140/90 mmHg. Prevalent CVD was
defined by the self-reported presence of coronary artery disease, myocardial infarction,
congestive heart failure, transient ischemic attack, or angina pectoris, and confirmed by
medical records. Where necessary, diagnostic determinations were confirmed by chart
review with permission.
Statistical analyses
Data were analysed with SPSS (Version 18, Chicago, IL, USA). Preliminary analyses were
performed to assess any significant correlations between dairy intake, cfPWV and other
demographic, health, nutrition and lifestyle factors. The dairy intakes in the sample were
calculated and the demographic, health and dietary characteristics of those who consume
dairy food at least once per day and those who consume less than this were tested for
differences using ANOVA or chi-square tests where appropriate. For the primary analyses,
univariate ANCOVA was used to compare cfPWV across increasing intakes of dairy food
consumption, ranging from never/seldom to at least once per day, and polynomial trend
analyses were performed across the five levels of dairy food intake only after the ANCOVA
test of the dairy intake main effect was found to be statistically significant (p<0.05). If the
omnibus test of overall differences among groups was observed, any significant trends were
reported. Adjustments for multiple comparisons among dairy food intake groups were made
and reported in terms of the Bonferroni adjustment.
An age-adjusted model was first performed, and then analyses followed using four covariate
sets. The extended covariate sets were as follows: (1) basic covariate set: age, sex, education
and race; (2) extended covariate set 1: basic set + height, weight, heart rate, antihypertensive
drug treatment (yes/no) and mean arterial pressure (MAP); (3) extended covariate set 2:
extended covariate set 1 + waist circumference, total cholesterol, HDL-cholesterol, and
LDL-cholesterol; (4) extended covariate set 3: extended covariate set 2 + depressive
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symptoms (CES-D raw score), intake of grains, vegetables, protein foods, empty calories
(sweets/fats/others), and total intake from all food groups (all in times per day).
As adjustment for height when assessing cfPWV has been recommended18, height and
weight were used in the basic set instead of BMI. However, alternative analyses (reported in
results) were done with height and weight removed and with waist circumference
substituted.
Variables were required to meet 1 of 2 criteria to be included as an additional covariate: 1)
significantly related (p< 0.05) to dairy food intake (the predictor) and cfPWV (the
primaryoutcome variable) to be included in the second extended model, or 2) differed
significantly between low (less than once per day) and high (at least daily) dairy consumers
to be included in the third extended model. Preliminary correlational analyses were
performed to ensure that MAP had the same relationship to cfPWV in each dairy intake
category. MAP was calculated as DBP + 1/3 (DBP - DBP). cfPWV was significantly
correlated with MAP for both low dairy consumers (<1 time per day, n=371), and high dairy
consumers (≥1 time/day, n=216), indicating that MAP has the same relationship to PWV
regardless of dairy intake. Additional analyses were performed with the inclusion of a dairy
intake x MAP interaction term.
Supplemental Table 1 shows those health and dietary variables that were significantly
correlated with both dairy food intake and cfPWV (please see http://hyper.ahajournals.org,
Table S1). While PWV and MAP, SBP and PP were highly correlated, they were used as
dependent variables in the current study. For all the models employed, covariates were
entered simultaneously with the predictor variables.
Results
The self-reported intakes of dairy foods (milk, cheese, yoghurt and dairy desserts, cream and
ice-cream) are shown in Table 1. Slightly over one-third of the sample (36.1%) reported
eating dairy food at least once per day. Half of participants (50.5%) reported eating dairy
foods between two and six times per week. The remaining participants (13.4%) reported
eating dairy foods no more than once per week. For individual foods, milk was the dairy
product consumed most frequently on a daily basis. Nearly one-third of the sample reported
drinking at least 600 mL of milk per day, equating to just over two serves per day. A similar
proportion of the sample consumed less than 150 mL per day, with the remaining
participants (37.9%) drinking between 150 and 450 mL per day. Of those that drank milk,
the majority reported drinking skim or reduced fat milk (80%). Cheese was most often
consumed between two and four times per week. Yoghurt, dairy desserts, cream and ice-
cream were consumed infrequently.
In Table 2, the demographic, health and nutritional characteristics of participants who
consumed dairy food at least daily (36.8%) are compared with those who consumed dairy
food less frequently than this (63.2%). Participants who consumed dairy on a daily basis
consumed more vegetables and protein foods, but fewer grains and empty calories (sweets/
fats), adjusting for total energy intake, compared to those who ate dairy less frequently than
this. They also had a higher number of years of education, lower body weight and waist
circumference, lower SBP and DBP, and fewer depressive symptoms (all P<0.05). More
females than males consumed dairy food on a daily basis.
There was a decrease in cfPWV, PP and SBP for participants across increasing intakes of
dairy food, ranging from never/seldom, to at least one time per day(Table 3). Table 3 shows
the 95 percent confidence limits associated with each mean for each group, and summarizes
the results of statistical analyses for the age-adjusted, basic and the most extended models. A
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table describing results for each covariate set for each dependent variable may be seen in the
supplemental data (please see http://hyper.ahajournals.org, Table S2).
For the age-adjusted model, the lowest cfPWV values (mean value 9.9 m/s) were observed
for those who consumed dairy products at least 5 to 6 times per week, and daily (mean value
10.0 m/s). With the addition of demographic variables, other cardiovascular risk factors and
nutrition variables, this significant linear trend across increasing intakes of dairy food
remained (extended covariate set 3). The cfPWV of those in the lowest three intake
categories (eat dairy 0 to 4 times per week) was significantly higher than the cfPWV for
those in the highest two intake categories (eat dairy at least 5 to 7 times per week)
(P=0.001). No associations between individual dairy foods (milk, cheese, yoghurt and dairy
desserts, cream and ice-cream) and cfPWV were found (all P>0.30).
The pattern of results was very similar for PP and SBP (Table 3). For all fully extended
models, PP and SBP decreased in a linear fashion as dairy food intake increased. Contrasts
performed between categories of intake showed that those who consumed dairy food at least
5 to 6 times per week had significantly lower PP and SBP than those who never or rarely
consumed dairy foods, after adjustment for demographic, cardiovascular and dietary factors.
Figure S1 (please see http://hyper.ahajournals.org) shows the reductions in cfPWV, PP and
SBP across increasing intakes of dairy food.
No significant differences among dairy intake groups were observed for DBP, waist
circumference, total cholesterol, HDL and LDL cholesterol, or triglyceride measures for
either the basic or extended models. These results are displayed in the supplemental data
(please see http://hyper.ahajournals.org, Table S2).
Additional analyses
The pattern of significant results remain unchanged when the following additional
regression models were employed: waist circumference was substituted for height and
weight, a MAP x dairy intake interaction was used in the model with MAP, and the addition
of physical activity to the extended covariate sets.
The analyses were repeated for participants not on any medication (n=218). Comparing
those who eat dairy less than daily (n=137) with those who eat dairy food at least daily
(n=81), the pattern of results for cfPWV were the same as for the whole sample, with the
high dairy consumers having a lower cfPWV in all covariate models (data not shown).
Discussion
Dairy product intake was inversely associated with cfPWV and SBP, with adjustment for
demographic, cardiovascular, and dietary factors. cfPWV, PP and SBP all decreased in a
linear fashion as dairy food intake increased across categories of intake from never/seldom
to 5 to 6 times per week or more. Importantly, we have also shown that dairy food intake is
not adversely associated with higher levels of cholesterol (total, HDL and LDL cholesterol)
or increased abdominal obesity (as measured by waist circumference). Moreover, our results
for cfPWV, the gold standard measure of arterial stiffness, were supported by our findings
for PP and SBP, surrogate hemodynamic indices of arterial stiffness.
These findings are consistent with research examining the effects of different milk-derived
proteins on BP and arterial stiffness. Peptides derived from milk protein, including
casokinins (casein-derived) and lactokinins (whey-derived) have been shown to inhibit
angiotensin-I-converting enzyme (ACE) activity, an important enzyme involved in BP
regulation19,20. Beneficial effects on BP and augmentation index have been reported for
Crichton et al. Page 6
Hypertension. Author manuscript; available in PMC 2013 May 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
both fermented milk rich in casein21–23, and rich in whey protein24,25. A more recent study
found that ionic calcium, in addition to lactic acid bacteria, released during milk
fermentation also contributed to ACE-inhibitory activity26. This small collection of research
does provide evidence for the role of probiotic dairy products in BP modification. Further
research is needed to determine their role in the treatment of arterial stiffness.
Our data supports one of the first intervention studies to examine the effects of low-fat dairy
product consumption on BP, in addition to other risk parameters of the metabolic
syndrome3. Consumption of three serves of low-fat dairy foods in overweight individuals
for eight weeks resulted in a significant reduction in SBP (2.9 ± 7.4 mmHg). The high dairy
diet showed no relationship with total cholesterol, LDL cholesterol or triglycerides.
Our findings also support studies that have examined dairy products without added
probiotics in relation to measures of CVD. These include a number of recent reviews,
including a meta-analysis by Elwood et al27 who found significant reductions in the relative
risk (RR) of ischemic heart disease, ischemic and hemorrhagic stroke in those who consume
the most milk, and other reviews of prospective studies which have failed to find a
consistent relationship between dairy food intake and coronary heart disease28,29. Most
recently, an increased consumption of yoghurt has been associated with carotid artery
intima-media thickness30, a marker of atherosclerotic vascular disease and predictor of
future cardiovascular and cerebrovascular events31. This study showed that women aged
over 70 years who consumed more than 100g of yoghurt per day had a significantly lower
carotid artery intima-media thickness than those with lower yoghurt intakes, after
adjustment for baseline, dietary and lifestyle risk factors. Higher milk, cheese or total dairy
intakes were not associated with carotid artery intima-media thickness, or with SBP or DBP.
An earlier prospective study found that yoghurt intake was associated with a lower risk of
acute myocardial infarction32, a clinical consequence of atherosclerotic vascular disease.
Little is known about the mechanisms by which dairy foods may improve BP or arterial
stiffening, a slow process resulting from changes in the extracellular matrix of the arterial
walls. The strongest evidence surrounds the role of bioactive peptides derived from dairy
protein, released during digestion, to inhibit ACE, modulate endothelial function and cause
vasodilatation33. Additional components of dairy are likely to play a role. High levels of
potassium have been associated with lower BP in numerous observational studies and
clinical trials34. Dietary potassium is thought to cause vasodilatation by stimulating the
sodium pump and opening potassium channels, as well as reducing vasoconstrictive
sensitivity to angiotensin II34. Magnesium modulates vascular tone and reactivity, stimulates
the production of vasodilators, improving blood flow and decreasing vascular resistance,
thereby lowering BP and increasing arterial function35. Phosphorus from dairy products has
recently been associated with lower BP and a reduced risk of incident hypertension in a
large prospective study36. Without a known mechanism on how dairy phosphorus may
reduce BP, it may be the combination of a range of nutrients in dairy foods that are effective
in modulating BP. Finally, dietary calcium has been linked with low BP, working in
combination with sodium, potassium and magnesium to ensure ionic balance, stabilise
vascular cell membranes and increase vasodilatation34. BP reduction may also be mediated
by body weight or fat reductions, as substantial evidence exists for an anti-obesity effect of
dairy37–39, and any positive effect on weight loss will be of benefit to BP.
Studies have reported that consumption of caffeinated tea and coffee affects PWV if
consumed immediately before PWV analyses40,41. Our participants consumed non-
caffeinated tea and coffee on the day of the examination. Coffee and tea consumption as a
routine part of the diet was not related to cfPWV, PP or BP.
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Although the differences in cfPWV and SBP according to dairy food intake in this study
were relatively small (difference of 1.0 m/s and 4.5 mm Hg between never/seldom and 5–6
times/week groups for cfPWV and SBP, respectively), the differences are likely to be
clinically significant. In a recent meta-analysis, it was estimated that for every 1 m/s
increase in cfPWV, there was an age-, sex- and risk factor-adjusted increase of 14%, 15%
and 15% in total CVD events, CVD mortality and all-cause mortality, respectively7. Clearly,
hypertension represents a modifiable risk factor with U.S. data suggesting that even small
reductions in BP can have a great public health impact and translate into substantial
reductions in coronary heart disease and stroke events 42,43. It has been estimated that a
reduction in SBP by 2 mm Hg may reduce the risk for stroke and myocardial infarction by
approximately 4%44.
A limitation to the study can be regarded as the lack of detailed information regarding
quantities of foods, including dairy food, consumed. Participants were asked ‘how often do
you eat the following foods?’, but not required to estimate portion or serving sizes.
Quantities are therefore likely to differ substantially amongst individuals as well as the same
individual on different occasions. Additionally, the range of responses to indicate how often
a food is consumed was limited in the high intake range, i.e. there was not a more specific
measure of intake beyond ‘once or more a day’. We are also unable to stipulate the fat
content of dairy food consumed based on information provided (with the exception of milk).
The study was cross-sectional and dietary measurement at only one point in time may not
reflect long-term consumption patterns. Secondly, the cross-sectional nature of the study
does not enable us to come to any conclusions regarding causality. We are unable to infer
that increasing dairy intake may decrease arterial stiffness. The age range in the present
study was wide, but we adjusted for age in our statistical analytic procedures because we did
not have sufficient numbers of subjects to examine results for multiple age groups over a
narrower range of ages. Finally, the MAP in this study was estimated using SBP and DBP,
and was not a true measure of MAP.
This study has a number of strengths. This is the first cross-sectional study that has
examined dairy food intake (not limited to fermented dairy products) and cfPWV as a
measure of arterial stiffness. We have examined this relationship in a large, community-
dwelling, healthy sample across a wide age span, and controlled for relevant demographic,
health and dietary variables.
Perspectives
Higher dairy food intake was associated with lower cfPWV and accompanying reductions of
PP and SBP. Further evidence from long-term longitudinal or intervention studies is needed
before the incorporation of dairy foods into a balanced diet for the attenuation of arterial
stiffening can be recommended, but this initial analysis of dairy consumption in relation to
arterial stiffness indicates that dairy consumption is not associated with a worsening of
traditional risk factors such as hypercholesterolemia and hypertension and may indeed have
benefits in reducing arterial stiffness.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Novelty and Significance
1) What is new?
• First study to examine the relationship between dairy food intake and arterial
stiffness, as measured by PWV.
2) What is relevant?
• Studies evaluating the relationship between dairy products and holistic markers
of cardiovascular disease risk, such as arterial stiffness have been recommended.
3)Summary
• Higher dairy food intake is associated with lower cfPWV, and lower SBP.
• Further intervention studies are needed to ascertain whether dairy food intake
may be an appropriate dietary intervention for management of arterial stiffening,
hypertension, and reducing cardiovascular disease risk.
Crichton et al. Page 12
Hypertension. Author manuscript; available in PMC 2013 May 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Crichton et al. Page 13
Ta
bl
e 
1
Se
lf-
re
po
rte
d 
in
ta
ke
s o
f c
he
es
e,
 y
og
hu
rt/
da
iry
 d
es
se
rts
, c
re
am
/ic
e-
cr
ea
m
, t
ot
al
 d
ai
ry
 fo
od
, a
nd
 m
ilk
 (N
=5
87
)
D
ai
ry
 p
ro
du
ct
D
ai
ry
 fo
od
 in
ta
ke
N
ev
er
/se
ld
om
1 
tim
e/
w
k
2–
4 
tim
es
/w
k
5–
6 
tim
es
/w
k
≥1
 ti
m
e/
da
y
n
 
(%
)
n
 
(%
)
n
 
(%
)
n
 
(%
)
n
 
(%
)
Ch
ee
se
92
 (1
5.7
)
14
7 
(25
.0)
24
5 
(41
.8)
70
 (1
1.9
)
33
 (5
.6)
Y
og
hu
rt 
&
 d
ai
ry
 d
es
se
rts
27
5 
(46
.8)
98
 (1
6.7
)
13
0 
(22
.1)
44
 (7
.5)
40
 (6
.8)
Cr
ea
m
 &
 ic
e-
cr
ea
m
29
4 
(50
.1)
16
4 
(28
.0)
10
0 
(17
.0)
21
 (3
.6)
8 
(1.
4)
To
ta
l d
ai
ry
 fo
od
37
 (6
.3)
40
 (6
.8)
14
1 
(24
.0)
15
3 
(26
.1)
21
6 
(36
.8)
0–
15
0 
m
L/
da
y
15
0 
m
L/
da
y
30
0 
m
L/
da
y
45
0 
m
L/
da
y
≥6
00
 m
L/
da
y
M
ilk
18
0 
(30
.7)
67
 (1
1.4
)
15
1 
(25
.7)
32
 (5
.5)
15
7 
(26
.7)
 
W
ho
le
 fa
t*
 
(5.
9%
)
13
 (4
0.6
)
3 
(9.
4)
6 
(18
.8)
1 
(3.
1)
7 
(21
.9)
 
Sk
im
/re
du
ce
d 
fa
t*
 
(80
.4%
)
12
6 
(28
.7)
53
 (1
2.1
)
10
3 
(23
.5)
27
 (6
.2)
12
4 
(28
.3)
 
O
th
er
 (e
.g.
 so
y)*
 
(13
.7%
)
28
 (3
7.3
)
7 
(9.
3)
12
 (1
6.0
)
3 
(4.
0)
23
 (3
0.7
)
*
%
 fr
om
 w
ith
in
 m
ilk
 g
ro
up
.
Hypertension. Author manuscript; available in PMC 2013 May 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Crichton et al. Page 14
Ta
bl
e 
2
D
em
og
ra
ph
ic
 v
ar
ia
bl
es
, h
ea
lth
 c
ha
ra
ct
er
ist
ic
s, 
an
d 
di
et
ar
y 
in
ta
ke
 o
f s
am
pl
e,
 c
om
pa
rin
g 
th
os
e 
w
ho
 c
on
su
m
e 
da
iry
 fo
od
 a
t l
ea
st 
on
ce
 p
er
 d
ay
 c
om
pa
re
d 
to
le
ss
 th
an
 th
is 
(N
=5
87
)
D
em
og
ra
ph
ic
/h
ea
lth
 ch
ar
ac
te
ri
st
ic
D
ai
ry
 fo
od
 <
 1
 ti
m
e/
da
y 
(n
=
37
1)
D
ai
ry
 fo
od
 a
t l
ea
st
 1
 ti
m
e/
da
y 
(n
=
21
6)
P*
M
ea
n
SD
M
ea
n
SD
A
ge
, y
63
.0
12
.7
65
.2
11
.6
.
03
9
Ed
uc
at
io
n,
 y
14
.4
2.
7
15
.0
2.
9
.
01
9
Ph
ys
ic
al
 a
ct
iv
ity
, M
ET
 h
ou
rs
/w
k
21
.2
27
.9
24
.6
26
.2
N
S
Sm
ok
in
g,
 c
ig
ar
et
te
s/w
k
9.
3
36
.8
5.
5
32
.2
N
S
W
ai
st 
ci
rc
um
fe
re
nc
e,
 c
m
95
.1
15
.1
91
.8
16
.5
.
01
5
W
ei
gh
t, 
kg
84
.3
19
.6
80
.8
18
.7
.
03
5
B
M
I, 
kg
/m
2
29
.9
6.
8
29
.1
6.
0
N
S
cf
PW
V
, m
/s
10
.4
2.
9
10
.1
2.
7
N
S
SB
P,
 m
m
 H
g
13
0.
9
20
.6
12
6.
8
18
.6
.
01
6
D
B
P,
 m
m
 H
g
78
.2
10
.2
75
.8
9.
5
.
00
5
M
A
P,
 m
m
 H
g
95
.8
12
.4
92
.8
11
.3
.
00
4
PP
, m
m
 H
g
52
.7
16
.2
51
.0
14
.7
N
S
H
ea
rt 
ra
te
, b
pm
60
.2
9.
6
59
.9
8.
9
N
S
To
ta
l c
ho
le
ste
ro
l, 
m
m
ol
/L
4.
8
1.
0
4.
9
1.
0
N
S
 
H
D
L 
ch
ol
es
te
ro
l, 
m
m
ol
/L
1.
4
0.
4
1.
4
0.
4
N
S
 
LD
L 
ch
ol
es
te
ro
l, 
m
m
ol
/L
2.
9
0.
8
2.
9
0.
8
N
S
 
Tr
ig
ly
ce
rid
es
, m
m
ol
/L
1.
3
0.
9
1.
3
0.
8
N
S
 
G
lu
co
se
, m
m
ol
/L
5.
5
1.
4
5.
4
1.
2
N
S
 
D
ep
re
ss
io
n,
 C
ES
-D
§
8.
6
7.
6
7.
1
7.
4
.
01
7
n
%
 (w
ith
in 
<1
 tim
e/d
ay
 gr
ou
p)
n
%
 (w
ith
in 
≥1
 tim
e/d
ay
 gr
ou
p)
P†
G
en
de
r
 
M
al
es
15
4
41
.5
70
32
.4
.
02
9
 
Fe
m
al
es
21
7
58
.5
14
6
67
.6
.
02
9
R
ac
e
 
W
hi
te
30
1
81
.1
20
3
94
.0
<
.0
01
Hypertension. Author manuscript; available in PMC 2013 May 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Crichton et al. Page 15
D
em
og
ra
ph
ic
/h
ea
lth
 ch
ar
ac
te
ri
st
ic
D
ai
ry
 fo
od
 <
 1
 ti
m
e/
da
y 
(n
=
37
1)
D
ai
ry
 fo
od
 a
t l
ea
st
 1
 ti
m
e/
da
y 
(n
=
21
6)
P*
M
ea
n
SD
M
ea
n
SD
 
O
th
er
70
18
.9
13
6.
0
<
.0
01
CV
D
||
41
11
.1
29
13
.4
N
S
D
ia
be
te
s m
el
lit
us
57
15
.4
30
13
.9
N
S
H
yp
er
te
ns
io
n
23
8
64
.2
12
2
56
.5
N
S
A
nt
i-h
yp
er
te
ns
iv
e 
m
ed
ic
at
io
n
20
4
55
.0
11
3
52
.3
N
S
Ch
ol
es
te
ro
l-l
ow
er
in
g 
m
ed
ic
at
io
n
13
0
35
.0
74
34
.3
N
S
D
ia
be
te
s m
ed
ic
at
io
n
50
13
.5
29
13
.4
N
S
M
ea
n
SE
M
M
ea
n
SE
M
P‡
G
ra
in
s/d
ay
3.
5
0.
08
3.
2
0.
10
.
01
0
Fr
ui
t/d
ay
1.
5
0.
05
1.
6
0.
07
N
S
V
eg
et
ab
le
s/d
ay
2.
6
0.
05
2.
9
0.
07
.
00
2
Pr
ot
ei
n 
fo
od
s/d
ay
1.
8
0.
04
1.
9
0.
05
.
02
4
O
th
er
 (f
ats
/sw
ee
ts)
/da
y
2.
1
0.
08
1.
5
0.
11
<
.0
01
A
lc
oh
ol
, s
ta
nd
ar
d 
dr
in
ks
/d
ay
0.
4
0.
04
0.
4
0.
05
N
S
To
ta
l a
ll 
fo
od
s s
er
ve
s/d
ay
¶
12
.0
3.
8
13
.5
4.
1
<
.0
01
B
M
I i
nd
ic
at
es
 b
od
y 
m
as
s i
nd
ex
; C
ES
-D
, C
en
tre
 fo
r E
pi
de
m
io
lo
gi
c 
St
ud
ie
s D
ep
re
ss
io
n 
Sc
al
e;
 c
fP
W
V
, c
ar
ot
id
-fe
m
or
al
 p
ul
se
 w
av
e 
ve
lo
ci
ty
; C
V
D
, c
ar
di
ov
as
cu
la
r d
ise
as
e;
 D
BP
, d
ia
sto
lic
 b
lo
od
 p
re
ss
ur
e;
H
D
L,
 h
ig
h-
de
ns
ity
 li
po
pr
ot
ei
n;
 L
D
L,
 lo
w
-d
en
sit
y 
lip
op
ro
te
in
; M
A
P,
 m
ea
n 
ar
te
ria
l p
re
ss
ur
e;
 M
ET
, m
et
ab
ol
ic
 e
qu
iv
al
en
t; 
PP
, p
ul
se
 p
re
ss
ur
e;
 S
BP
, s
ys
to
lic
 b
lo
od
 p
re
ss
ur
e.
*
A
na
ly
sis
 o
f v
ar
ia
nc
e 
fo
r c
on
tin
uo
us
 v
ar
ia
bl
es
.
† C
hi
 sq
ua
re
 fo
r c
at
eg
or
ic
al
 v
ar
ia
bl
es
.
‡ A
na
ly
sis
 o
f c
ov
ar
ia
nc
e,
 c
on
tro
lli
ng
 fo
r t
ot
al
 se
rv
es
 p
er
 d
ay
 a
ll 
fo
od
 g
ro
up
s.
§ C
ES
-D
: h
ig
he
r s
co
re
 in
di
ca
te
s g
re
at
er
 n
um
be
r o
f d
ep
re
ss
iv
e 
sy
m
pt
om
s.
|| C
V
D
 w
as
 d
ef
in
ed
 a
s p
re
se
nt
 if
 th
er
e 
w
as
 se
lf-
re
po
rte
d 
hi
sto
ry
 o
f c
or
on
ar
y 
ar
te
ry
 d
ise
as
e,
 m
yo
ca
rd
ia
l i
nf
ar
ct
io
n,
 c
on
ge
sti
ve
 h
ea
rt 
fa
ilu
re
, t
ra
ns
ie
nt
 is
ch
em
ic
 a
tta
ck
, o
r a
ng
in
a 
pe
ct
or
is.
¶ M
ea
n 
an
d 
SD
, i
nc
lu
de
s a
lc
oh
ol
.
Hypertension. Author manuscript; available in PMC 2013 May 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Crichton et al. Page 16
Ta
bl
e 
3
R
es
ul
ts 
of
 a
na
ly
sis
 o
f c
ov
ar
ia
nc
e,
 sh
ow
in
g 
as
so
ci
at
io
ns
 b
et
w
ee
n 
cf
PW
V
, P
P,
 a
nd
 S
BP
 a
cr
os
s i
nc
re
as
in
g 
in
ta
ke
s o
f d
ai
ry
 fo
od
 (N
=5
87
), f
or 
ba
sic
 an
d
ex
te
nd
ed
 c
ov
ar
ia
te
 se
t 3
O
ut
co
m
e m
ea
su
re
C
ov
ar
ia
te
 se
t
D
ai
ry
 fo
od
 in
ta
ke
P*
N
ev
er
/se
ld
om
1 
tim
e/
w
ee
k
2–
4 
tim
es
/w
ee
k
5–
6 
tim
es
/w
ee
k
≥1
/d
ay
n
 
=
 3
7
n
 
=
 4
0
n
 
=
 1
41
n
 
=
 1
53
n
 
=
 2
16
M
ea
n
95
%
 C
I
M
ea
n
95
%
 C
I
M
ea
n
95
%
 C
I
M
ea
n
95
%
 C
I
M
ea
n
95
%
 C
I
cf
PW
V
A
ge
-a
dju
ste
d
10
.8
10
.0
, 1
1.
5
11
.1
10
.4
, 1
1.
8
10
.8
10
.4
, 1
1.
2
9.
9||¶
9.
6,
 1
0.
3
10
.0
¶
9.
7,
 1
0.
3
.
00
0‡
B
as
ic
10
.6
9.
8,
 1
1.
4
10
.9
10
.2
, 1
1.
6
10
.7
10
.3
, 1
1.
1
10
.0
9.
6,
10
.3
10
.1
9.
7,
 1
0.
4
.
01
6†
Ex
te
nd
ed
 3
11
.0
10
.3
, 1
1.
7
10
.8
10
.1
, 1
1.
5
10
.6
10
.3
, 1
1.
0
10
.0
9.
6,
10
.3
10
.1
9.
8,
 1
0.
4
.
01
8‡
PP
A
ge
-a
dju
ste
d
56
.3
51
.9
, 6
0.
7
57
.8
53
.5
, 6
2.
1
53
.2
50
.9
, 5
5.
5
51
.3
49
.1
, 5
3.
4
50
.2
||
48
.3
, 5
2.
0
.
00
3‡
B
as
ic
56
.3
51
.9
, 6
0.
6
56
.6
52
.3
, 6
0.
9
52
.7
§
50
.5
, 5
5.
0
51
.4
§
49
.2
, 5
3.
5
50
.6
§
48
.8
, 5
2.
4
.
03
5‡
Ex
te
nd
ed
 3
57
.6
54
.1
, 6
1.
0
53
.1
49
.8
, 5
6.
5
52
.4
50
.6
, 5
4.
1
50
.8
§
49
.2
, 5
2.
4
51
.6
§
50
.2
, 5
3.
0
.
01
3‡
SB
P
A
ge
-a
dju
ste
d
13
1.
8
12
5.
6,
 1
37
.9
13
8.
7
13
2.
7,
 1
44
.6
13
1.
7
12
8.
5,
 1
34
.8
12
8.
8||
12
5.
8,
 1
31
.9
12
6.
1||
12
3.
6,
 1
28
.7
.
00
1‡
B
as
ic
13
0.
1
12
4.
1,
 1
36
.2
13
5.
9
13
0.
1,
 1
41
.8
13
0.
4
12
7.
3,
 1
33
.4
12
9.
5
12
6.
5,
 1
32
.4
12
7.
4
12
4.
8,
 1
29
.9
N
S
Ex
te
nd
ed
 3
13
3.
0
13
0.
7,
 1
35
.3
13
0.
1
12
7.
8,
 1
32
.3
12
9.
6
12
8.
4,
 1
30
.7
12
8.
5§
12
7.
4,
 1
29
.6
12
9.
1§
12
8.
1,
 1
30
.0
.
01
3‡
CE
S-
D
 in
di
ca
te
s C
en
tre
 fo
r E
pi
de
m
io
lo
gi
c 
St
ud
ie
s D
ep
re
ss
io
n 
Sc
al
e;
 c
fP
W
V
, c
ar
ot
id
-fe
m
or
al
 p
ul
se
 w
av
e 
ve
lo
ci
ty
; H
D
L,
 h
ig
h-
de
ns
ity
 li
po
pr
ot
ei
n;
 L
D
L,
 lo
w
-d
en
sit
y 
lip
op
ro
te
in
; P
P,
 p
ul
se
 p
re
ss
ur
e;
 S
BP
,
sy
sto
lic
 b
lo
od
 p
re
ss
ur
e;
 W
C,
 w
ai
st 
ci
rc
um
fe
re
nc
e.
A
ge
-a
dju
ste
d: 
ad
jus
ted
 fo
r a
ge
.
B
as
ic
 se
t: 
ad
jus
ted
 fo
r a
ge
, e
du
cat
ion
, g
en
de
r, r
ace
.
Ex
te
nd
ed
 se
t 3
: a
dju
ste
d f
or 
va
ria
ble
s i
n b
asi
c s
et 
+ h
eig
ht,
 w
eig
ht,
 he
art
 ra
te,
 an
tih
yp
ert
en
siv
e d
rug
 tre
atm
en
t, m
ean
 ar
ter
ial
 pr
ess
ure
, W
C,
 to
tal
 ch
ole
ste
rol
, H
DL
- a
nd
 LD
L-
ch
ole
ste
rol
, C
ES
-D
 ra
w 
sco
re 
+
gr
ai
ns
/d
ay
, v
eg
et
ab
le
s/d
ay
, s
w
ee
ts/
da
y,
 p
ro
te
in
/d
ay
, t
ot
al
 fo
od
 se
rv
es
/d
ay
.
*
P 
fo
r o
ve
ra
ll 
om
ni
bu
s o
ut
co
m
e.
† P
 
<
0.
05
,
‡ P
 
<
0.
01
, f
or
 st
at
ist
ic
al
ly
 si
gn
ifi
ca
nt
 li
ne
ar
 tr
en
d.
§ s
ig
ni
fic
an
tly
 d
iff
er
en
t f
ro
m
 th
e 
ne
ve
r/s
el
do
m
 g
ro
up
.
|| si
gn
ifi
ca
nt
ly
 d
iff
er
en
t f
ro
m
 1
 ti
m
e/
w
ee
k 
gr
ou
p.
¶ si
gn
ifi
ca
nt
ly
 d
iff
er
en
t f
ro
m
 th
e 
2–
4 
tim
es
/w
ee
k 
gr
ou
p.
Hypertension. Author manuscript; available in PMC 2013 May 01.
